CIF + mesalazine

CIF + mesalazine is a combination therapy consisting of a Chinese medicine intestine formula (CIF) and mesalazine, an aminosalicylate anti-inflammatory drug. This combination has been studied for the treatment of chronic ulcerative colitis (UC). Mesalazine acts locally in the colon to reduce inflammation, likely by modulating cyclooxygenase and lipooxygenase pathways, thereby decreasing prostaglandin and leukotriene synthesis. CIF is a novel herbal enema formulation that, when combined with oral mesalazine, has demonstrated improved clinical outcomes in UC patients compared to mesalazine alone. The addition of CIF further reduces pro-inflammatory markers such as tumor necrosis factor-alpha (TNF-α) and hypersensitivity C-reactive protein (hs-CRP), while increasing anti-inflammatory interleukin-4 (IL-4), suggesting enhanced regulation of inflammatory processes[2][1]. The precise composition of CIF is not specified in the available literature.